ASCO 2023 | Promising results of cabozantinib plus nivolumab in non-clear cell RCC

Chung-Han Lee, MD, PhD, from Memorial Sloan Kettering Cancer Center, New York, NY, discusses the promising results of the Phase II (NCT03635892) trial of cabozantinib plus nivolumab for non-clear cell renal cell carcinoma (RCC). The trial showed a 48% objective response rate (ORR) and a median progression-free survival (PFS) of 13 months in patients with papillary, unclassified, or translocation associated RCC. Median overall survival (OS) was 28 months, and the therapy demonstrated favorable safety profiles. These updated findings suggest that cabozantinib plus nivolumab could be an effective and well-tolerated treatment option for patients with metastatic non-clear cell RCC with certain histologies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved